Global biotechnology company BioCryst Pharmaceuticals Inc. (BCRX) is approaching an indispensable regulatory moment with the FDA expected to deliver its decision on December 12, 2025, regarding the approval of ORLADEYO Oral Granules for pediatric patients aged 2 to 11 years with hereditary angioedema (HAE).
Much Hinges On The FDA's Verdict
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com